Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis.
Multiple sclerosis in 2014: Progress in MS-classification, mechanisms and treatment.
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis.
Pattern of remyelination in the CNS.
Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Mitoxantrone: benefits and risks in multiple sclerosis patients.
[Assessment of the pain patients with the multiple sclerosis after applying the physiotherapy treatment].
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
Interferon-beta is a potent promoter of nerve growth factor production by astrocytes.
Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years.
Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.
Flupirtine as Oral Treatment in Multiple Sclerosis (FLORIMS)
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Emerging oral agents for multiple sclerosis.
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
Headache in relapse and remission phases of multiple sclerosis: A case-control study.
Combination therapy in patients with relapsing-remitting multiple sclerosis (MS) CombiRx
Effect of disease duration on personality type in multiple sclerosis patients and healthy individual.
Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.
FDA approves Genzyme’s AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing multiple sclerosis
Dimethyl fumarate (BG-12, Tecfidera) - NICE says yes in draft final guidance
Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process.
Genpharm and Genzyme Aubagio ® agreement for the MENA region

Pages